Overview

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

Status:
Recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to determine if adjuvant apalutamide in prostate cancer patients at high risk of developing subsequent metastatic disease results in prolonged biochemically recurrence-free survival after radical prostatectomy (RPE) in comparison to standard of care (SOC).
Phase:
Phase 2
Details
Lead Sponsor:
Westfälische Wilhelms-Universität Münster
Collaborator:
Janssen Pharmaceutica N.V., Belgium